Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

被引：0

作者：

Paiva, Bruno ^{[1
]}

Mateos, Maria-Victoria ^{[2
]}

Ignacio Sanchez-Abarca, Luis ^{[3
]}

Belen Vidriales, Maria ^{[4
]}

Lopez-Corral, Lucia ^{[5
]}

Corchete, Luis A. ^{[5
]}

Hernandez, Miguel T. ^{[6
]}

Bargay, Joan ^{[7
]}

De Arriba, Felipe ^{[8
]}

De la Rubia, Javier ^{[9
]}

Isabel Teruel, Ana ^{[10
]}

Giraldo, Pilar ^{[11
]}

Rosinol, Laura ^{[12
]}

Prosper, Felipe ^{[13
]}

Oriol, Albert ^{[14
]}

Mariano Hernandez, Jose ^{[15
]}

Esteves, Graca ^{[16
]}

da Costa, Fernando Leal ^{[17
]}

Jose Lahuerta, Juan ^{[18
]}

Blade, Joan ^{[12
]}

Perez-Simon, Jose A. ^{[19
]}

San Miguel, Jesus ^{[20
]}

机构：

[1] Univ Navarra Clin, Dept Hematol & Immunol, Pamplona, Spain

[2] Univ Hosp Salamanca IBSAL, Dept Hematol, Salamanca, Spain

[3] IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain

[4] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain

[5] Hosp Univ Salamanca, Salamanca, Spain

[6] Univ Hosp, Santa Cruz, CA USA

[7] Hosp Son Llatzer, Palma de Mallorca, Spain

[8] Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Hematol & Clin Oncol Unit, Murcia, Spain

[9] HUP La Fe, Valencia, Spain

[10] Hosp Clin Valencia, Valencia, Spain

[11] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia

[12] Hosp Clin Barcelona, Barcelona, Spain

[13] Univ Navarra Clin, Pamplona, Spain

[14] Hosp Badalona Germans Trias & Pujol, lnst Catala Oncol, Barcelona, Spain

[15] Hosp Gen Segovia, Segovia, Spain

[16] Hosp Santa Maria, Lisbon, Portugal

[17] nst Portugues Oncol, Lisbon, Portugal

[18] Hosp 12 Octubre, E-28041 Madrid, Spain

[19] Hosp Univ Virgen Rocio, Dept Hematol, Seville, Spain

[20] Univ Navarra, Univ Navarra Clin, Ctr Invest Med Aplicada, E-31080 Pamplona, Spain

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
Sung-Eun Lee
Ji-Young Lim
Da-Bin Ryu
Tae Woo Kim
Jae-Ho Yoon
Byung-Sik Cho
Ki-Seong Eom
Yoo-Jin Kim
Hee-Je Kim
Seok Lee
Seok-Goo Cho
Dong-Wook Kim
Jong-Wook Lee
Woo-Sung Min
Myungshin Kim
Chang-Ki Min
Cancer Immunology, Immunotherapy, 2016, 65 : 983 - 994
[32] Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
Lee, Sung-Eun
Lim, Ji-Young
Ryu, Da-Bin
Kim, Tae Woo
Yoon, Jae-Ho
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Kim, Hee-Je
Lee, Seok
Cho, Seok-Goo
Kim, Dong-Wook
Lee, Jong-Wook
Min, Woo-Sung
Kim, Myungshin
Min, Chang-Ki
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (08) : 983 - 994
[33] Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd - R) In High Risk Smoldering Multiple Myeloma Patients
Landgren, Ola
Mailankody, Sham
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Zingone, Adriana
Costello, Rene
Burton, Debra
Zhang, Yong
Wu, Peter
Carter, George
Mulquin, Marcia
Zuchlinski, Diamond
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Lindenberg, Liza
Kurdziel, Karen
Choyke, Peter
Steinberg, Seth M.
Roschewski, Mark
Korde, Neha
BLOOD, 2013, 122 (21)
[34] Phase III trial of thalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
不详
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 452 - 453
[35] Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone
Paiva, Bruno
Lopez-Corral, Lucia
Vidriales, Maria-Belen
Sanchez Abarca, Luis Ignacio
Hernandez, Miguel T.
Bargay, Joan
De La Rubia, Javier
Giraldo, Pilar
Teruel, Ana-Isabel
Rosinol, Laura
Oriol, Albert
Hernandez, Jose
de Arriba, Felipe
Esteves, Graca
Perez Simon, Jose Antonio
Mateos, Maria-Victoria
San Miguel, Jesus F.
BLOOD, 2010, 116 (21) : 794 - 795
[36] Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
Baz, Rachid C.
Shain, Kenneth H.
Hussein, Mohamad A.
Lee, Ji-Hyun
Sullivan, Daniel M.
Oliver, Elizabeth Finley
Nardelli, Lisa A.
Nodzon, Lisa A.
Zhao, Xiuhua
Ochoa-Bayona, Jose Leonel
Nishihori, Taiga
Dalton, William S.
Alsina, Melissa
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) : 62 - 67
[37] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Moreau, Philippe
Richardson, Paul Gerard Guy
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc
Facon, Thierry
Vij, Ravi
Reece, Donna Ellen
White, Darrell
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn Scott
Singhal, Anil
Lonial, Sagar
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study
Jagannath, Sundar
Lonial, Sagar
Jakubowiak, Andrzej J.
Facon, Thierry
Vij, Ravi
Raab, Marc S.
White, Darrell J.
Wang, Min-Hui
Parli, Teresa
Bartlett, Blake J.
Singhal, Anil K.
Richardson, Paul G.
BLOOD, 2011, 118 (21) : 1697 - 1698
[39] Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Koh, Youngil
Martinez-Lopez, Joaquin
Parmar, Gurdeep
Prince, H. Miles
Quach, Hang
Ribas, Paz
Hermansen, Emil
Hungria, Vania T. M.
Besisik, Sevgi Kalayoglu
Kim, Jin Seok
Leleu, Xavier
Peceliunas, Valdas
Schjesvold, Fredrik
Sevindik, Omur G.
Lavrova, Tatiana
Dubin, Franck
Devisme, Christine
Lepine, Lucie
Mace, Sandrine
Morisse, Mony
Ghobrial, Irene
BLOOD, 2022, 140 : 7317 - 7319
[40] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. Vincent
Jacobus, Susanna
Callander, Natalie S.
Fonseca, Rafael
Vesole, David H.
Williams, Michael E.
Abonour, Rafat
Siegel, David S.
Katz, Michael
Greipp, Philip R.
LANCET ONCOLOGY, 2010, 11 (01): : 29 - 37

← 1 2 3 4 5 →